受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C16H14Cl2N8O |
|||
分子量 | 405.24 | CAS No. | 2241300-51-4 | |
Solubility (25°C)* | 体外 | DMSO | 81 mg/mL (199.88 mM) | |
Water | 50 mg/mL (123.38 mM) | |||
Ethanol | ˂1 mg/mL | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells. |
---|---|
in vitro | AS2863619 induction of Foxp3 in vitro does not require exogenous TGF-β. AS2863619-induced iTreg cells can be induced in the presence of inflammatory cytokines such as IL-4, IL-6, and IFN-γ, which appear to hamper Foxp3 gene activation via activation of STATs. AS2863619 is able to generate iTreg cells not only from naïve Tconv cells but also from effector/memory Tconv cells. Furthermore, AS2863619 cannot induce Foxp3 in CDK8 and CDK19 double-deficient T cells. AS2863619-induced iTreg cells require TCR and IL-2 stimulation for their generation and are devoid of Treg-type DNA hypomethylation, which is present in nTreg cells and required for stable Treg function.[1] |
in vivo | AS2863619 induces in vivo Foxp3 induction in antigen-activated T cells. In vivo AS2863619-induced Foxp3+ T cells are able to gradually acquire Treg-specific epigenetic alterations, differentiating into functionally stable Foxp3+ pTreg cells having a more nTreg-like gene expression profile.[1] |
細胞アッセイ | 細胞株 | PBMCs, Human CD4+ T cells, lymph node cells derived from eFox mice |
---|---|---|
濃度 | 1.0 μM | |
反応時間 | 24 h, 0-44 h | |
実験の流れ | 2 × 105 CD4+ DO11.10 T cells are plated with 4 × 104 T cell–depleted splenocytes in the presence of 5 μM OVA peptide. AS2863619 is used at 1.0 μM, except where noted. |
|
動物実験 | 動物モデル | C57BL/6, BALB/c, NOD, and BALB/c-nu/nu mice |
投薬量 | 30 mg/kg | |
投与方法 | Oral gavage |
Enhanced T cell effector activity by targeting the Mediator kinase module [ Science, 2022, 378(6620):eabn5647] | PubMed: 36356142 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。